A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects.
Latest Information Update: 27 Jul 2022
At a glance
- Drugs Dapiglutide (Primary)
- Indications Gastrointestinal disorders; Short bowel syndrome
- Focus Adverse reactions
- Sponsors Zealand Pharma
Most Recent Events
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 06 Jun 2022 Results presented in a Zealand Pharma Media Release.
- 06 Jun 2022 According to a Zealand Pharma media release, data presented at the 82nd Scientific Sessions of the American Diabetes Association (ADA).